A critical and comprehensive look at current state-of-the-art scientific and translational research being conducted internationally, in academia and industry, to address new ways to provide effective treatment to victims of ischemic and hemorrhagic stroke and other ischemic diseases. Currently stroke can be successfully treated through the administration of a thrombolytic, but the therapeutic window is short and many patients are not able to receive treatment. Only about 30% of patients are “cured” by available treatments. In 5 sections, the proposed volume will explore historical and novel neuroprotection mechanisms and targets, new and combination therapies, as well as clinical trial design for some of the recent bench-side research.
Paul Lapchak is the director of translational neurodegenerative disease research at Cedars-Sinai Medical Center in California. Dr. Lapchak obtained his Ph.D. at McGill University and University of Southern California. His lab focuses on developing new therapeutic approaches to treat different types of stroke as well as experimenting with neuroprotective agents. In addition, his research extends to drug development using the rabbit embolic stroke model and multiple assay methods. Dr. Lapchak is editor-in-chief of the Journal of Neurology & Neurophysiology and associate editor of the journal Translational Stroke Research. With over twenty years of experience and numerous publications, Dr. Lapchak is a leading expert in his field of translational stroke research.
This book is a critical and comprehensive look at current state-of-the-art scientific and translational research being conducted internationally, in both academia and industry; it serves to address new ways to provide effective treatment to victims of ischemic and hemorrhagic stroke and other ischemic diseases. Currently, stroke can be successfully treated through the administration of a thrombolytic, but the therapeutic window is short and many patients are not able to receive treatment. Only about 30% of patients are “cured” by available treatments. Divided into five sections, the proposed volume explores historical and novel neuroprotection mechanisms and targets, new and combination therapies, as well as clinical trial design for some of the most recent bench-side research. Multifaceted discussion of stroke neuroprotection–from its history to models, research, and clinical relevance
